Skip to main content
NUVL
NASDAQ Life Sciences

Nuvalent's $10.6B sale to GSK clears a key antitrust hurdle as the HSR waiting period expires

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$123.77
Mkt Cap
$9.782B
52W Low
$71.13
52W High
$123.86
52W Position info
74% above low
Off High info
at 52W high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NUVL sits 74% above its 52-week low of $71.13.

Summary

Nuvalent disclosed that the HSR waiting period for its $10.6 billion acquisition by GSK expired on July 9, 2026, satisfying a key antitrust condition. The tender offer of $124 per share remains subject to other closing conditions.


Key Events · M&A and Partnerships · NUVL

  • HSR Waiting Period Expires

    The required waiting period under the HSR Act expired at 11:59 p.m. ET on July 9, 2026, satisfying the antitrust condition for GSK's tender offer.

  • Deal Remains Subject to Other Conditions

    While antitrust clearance removes a significant regulatory risk, the Offer and Merger still require other customary closing conditions.

  • Tender Offer Price Unchanged

    GSK's all-cash offer of $124.00 per share remains in effect, representing a premium to Nuvalent's pre-announcement trading price.

  • Next Steps Toward Closing

    With HSR clearance obtained, the parties can proceed toward satisfying remaining conditions and closing the transaction.


Analysis · NUVL · Life Sciences

With the HSR waiting period now expired, a major regulatory condition for GSK's $124/share all-cash tender offer has been removed. Antitrust clearance significantly de-risks the path to closing, though other customary conditions remain. This milestone marks a critical step forward in the acquisition process.

How filings like this one have moved

In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NUVL was trading at $123.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.86. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NUVL - Latest Insights

NUVL
Jul 15, 2026, 9:03 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $123.97
Real-time Price: $123.97 info
Change: $0 (0%) info
Market Cap: $9.793B info
NUVL
Jul 15, 2026, 9:00 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Price at Filing: $123.97
Real-time Price: $123.97 info
Change: $0 (0%) info
Market Cap: $9.793B info
NUVL
Jul 15, 2026, 8:59 AM EDT
Filing Type: SC 14D9/A
Importance Score:
9
Price at Filing: $123.97
Real-time Price: $123.97 info
Change: $0 (0%) info
Market Cap: $9.793B info
NUVL
Jul 10, 2026, 8:44 AM EDT
Filing Type: SC TO-T/A
Importance Score:
9
Price at Filing: $123.87
Real-time Price: $123.97 info
Change: +$0.100 (+0.08%) info
Market Cap: $9.793B info
NUVL
Jul 07, 2026, 4:30 PM EDT
Filing Type: SC 14D9/A
Importance Score:
9
Price at Filing: $123.77
Real-time Price: $123.97 info
Change: +$0.200 (+0.16%) info
Market Cap: $9.793B info